Revenue Breakdown
Composition ()
No data
Revenue Streams
Codexis Inc (CDXS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Performance Enzymes, accounting for 93.9% of total sales, equivalent to $8.71M. Other significant revenue streams include Product Revenue and Research and development revenue. Understanding this composition is critical for investors evaluating how CDXS navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Codexis Inc maintains a gross margin of 71.34%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -220.31%, while the net margin is -228.05%. These profitability ratios, combined with a Return on Equity (ROE) of -114.26%, provide a clear picture of how effectively CDXS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CDXS competes directly with industry leaders such as AMTX and EXOZ. With a market capitalization of $92.13M, it holds a significant position in the sector. When comparing efficiency, CDXS's gross margin of 71.34% stands against AMTX's -1.89% and EXOZ's N/A. Such benchmarking helps identify whether Codexis Inc is trading at a premium or discount relative to its financial performance.
